KIMCO

What KIMCO does

KIMCo (Korea Innovative Medicines Consortium / 한국혁신의약품컨소시엄) is a Seoul-based non-profit incorporated foundation (재단법인) established in August 2020 by 59 Korean pharmaceutical and biotech companies together with the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA). It was capitalized with approximately 70 billion KRW in founding contributions and operates as Korea's first dedicated pharma-biotech open innovation platform. Its functional purpose is to pool industry resources and capabilities to address challenges (large-scale R&D, late-stage clinical development, manufacturing modernization, global market entry) that individual Korean pharma companies cannot tackle alone, using a "Relay of Innovation" model that connects biotech ventures, mid/large-cap pharma members, and global Big Pharma partners.

The platform's core deliverables are: (1) the KIMCo Innovation Track, a structured twice-yearly investment and acceleration cycle for biotech ventures delivered through bridge.kimc.or.kr; (2) the Startup Korea KIMCo-Yuanta Bio Fund, a 157 billion KRW pharmaceutical company union bio-specialized fund co-managed with Yuanta Investment; (3) government program administration across the Ministry of SMEs and Startups (smart factory construction, 19.95 billion KRW; QbD system rollout with MFDS, 2.73 billion KRW), Ministry of Trade, Industry and Energy (mRNA vaccine raw material localization, 18.1 billion KRW for 5 companies; TBM global commercialization, 13 billion KRW for 7 companies plus 201.65 billion KRW total budget); and (4) cross-border partnership events with J&J JLABS, Boehringer Ingelheim/BIVF, Syneos Health, and Japanese Big Pharma (Takeda, Astellas, Mitsubishi Tanabe). Direct strategic investments include 1 billion KRW in Arkgen BioScions (AMB-TCE immuno-oncology platform) and 100 million KRW in Neumous (BBB-modulating ultrasound device, MFDS innovative medical device No. 80).

KIMCo's economic model combines member contributions (subscription-like annual commitments from the 59 member companies and KPBMA), government project execution fees from multi-ministry programs, GP management economics from the KIMCo-Yuanta Bio Fund, and carried interest/returns from direct strategic investments in portfolio companies. It does not sell commercial products; instead, it distributes services through direct engagement with member pharma companies, biotech ventures, and international partners via the foundation's own platform, partnering events (Nordic Life Science Days, BIO China, East-West Biopharma Summit, Korea-Japan Bio Roundtables), and formal MOUs with Seoul BioHub, Bae Kim & Lee LLC, Yonsei and SNU tech holdings, and Creative Economy & Innovation Centers. The organization is lean, with 8 foundation secretariat staff augmented by an Operating Committee of approximately 20 industry experts covering R&D, BD, clinical, regulatory, manufacturing, quality, investment, legal, and accounting functions.

Name

KIMCO

Legal name

재단법인 한국혁신의약품컨소시엄

Website

https://kimc.or.kr

Company type

Private

Founded year

2020

Operating status

Operating

Short description

KIMCo (Korea Innovative Medicines Consortium) is a Seoul-based non-profit foundation that operates a K-Bio open innovation platform connecting 59 Korean pharmaceutical member companies, biotech startups, and global Big Pharma partners through co-investment, acceleration programs, and government-backed industry initiatives.

Ownership category

akta.pro rank

Product category

Pharmaceutical-Biotech Open Innovation Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Management of Companies and Enterprises (551), Professional, Scientific, and Technical Services (541)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Biopharma open innovation
• Pharmaceutical venture investment
• Biotech acceleration programs
• Public-private partnerships
• K-bio collaboration platform

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Member Contributions: KIMCo is a non-profit incorporated foundation established with contributions from 59 pharmaceutical and biotech companies and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA). Initial founding contributions totaled approximately 70 billion KRW.
2. Government Project Execution: KIMCo executes government-funded programs including smart factory support (19.95 billion KRW supported), QbD system roll-out (2.73 billion KRW), mRNA vaccine raw material production technology development (18.1 billion KRW for 5 companies), and TBM development project (13 billion KRW for 7 companies).
3. KIMCo-Yuanta Bio Fund Management: KIMCo co-operates the 'Startup Korea KIMCo-Yuanta Bio Fund' (157 billion KRW scale) with Yuanta Investment, generating returns through successful biotech venture investments.
4. Strategic Investment Returns: KIMCo makes direct strategic investments in early-stage biotech ventures (e.g., 100 million KRW in Neumous, 1 billion KRW in Arkgen BioScions) and earns returns upon successful exit or partnership.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

KIMCo is a non-profit incorporated foundation that operates a K-Bio open innovation platform connecting biotech ventures, pharmaceutical member companies, and global Big Pharma through co-investment and co-development. It runs the KIMCo Innovation Track acceleration program, co-manages the 157 billion KRW KIMCo-Yuanta Bio Fund, and executes Korean government-designated public-private partnership programs including smart factory, QbD, mRNA vaccine raw material, and TBM global commercialization initiatives. The platform serves 59–60 pharmaceutical and biotech member companies plus selected biotech ventures with strategic investment, acceleration support, and global partnership facilitation.

Product overview

KIMCO (Korea Innovative Medicines Consortium) is a non-profit incorporated foundation established by 59 pharmaceutical and biotech companies along with the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA). It operates as a K-Bio Open Innovation Platform designed to tackle industry challenges that individual companies cannot achieve alone. The organization offers multiple interconnected programs including the KIMCo Innovation Track for biotech venture acceleration, the Startup Korea KIMCo-Yuanta Bio Fund (157 billion KRW), and Public-Private Partnership Programs. Additionally, KIMCO runs specialized projects including Smart Factory Programs, QbD System Roll-out Support, Technology-Based Medicine (TBM) Global Commercialization, and mRNA Vaccine Raw Material Development initiatives. The platform facilitates collaboration between ventures, pharmaceutical companies, and global partners through its 'Relay of Innovation' model.

Differentiator

Problem solved

Functional benefit

Products and services

• KIMCo Innovation Track
• Startup Korea KIMCo-Yuanta Bio Fund
• K-Bio Open Innovation Platform
• Smart Factory Program
• QbD System Roll-out Supporting Project
• Technology-Based Medicine (TBM) Global Commercialization
• mRNA Vaccine Raw Material Development Program
• Korea-Europe Biomedical Partnership Project

Quantifiable outcome

• KIMCo-Yuanta Bio Fund: 157 billion KRW pharmaceutical company union bio-specialized fund — first of its kind in Korea's industry
• +6 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

24 partnerships are on record, tiered core, minor and major.

• Seoul BioHub (서울바이오허브)coreStrategic or Co-development Partner · 9 March 2026KIMCo and Seoul BioHub signed an MOU for open innovation promotion for domestic biotech startups. They are co-operating the 'Bio Open Innovation Chain' business in 2025, supporting joint research and technology transfer between startups and large/mid-sized pharmaceutical companies, and promoting the 'Relay of Innovation' connecting ventures-pharma-Global partners. They also co-hosted the East-West Biopharma Summit Pre-event and the 2025 Seoul Bio-Medical Open Collaboration event.
• ARKgen BioScions (아크젠바이오사이온스)coreStrategic or Co-development Partner · 28 January 2026KIMCo made a 10 billion KRW strategic investment in Arkgen BioScions, the first portfolio company of the KIMCo-Yuanta Pharmaceutical Company Union Fund. Arkgen BioScions is developing next-generation immuno-oncology drugs using its AMB-TCE multi-antibody platform technology. KIMCo is simultaneously pursuing pharmaceutical company cooperation and commercialization linkage alongside the investment.
• Syneos Health (시네오스 헬스)coreStrategic or Co-development Partner · 23 January 2026KIMCo and Syneos Health co-hosted 'Korea Biopharma Executive Roundtable 2025' addressing strategic response of K-biopharma to changing US market conditions under Trump administration. Syneos Health experts presented on FDA policy changes, pricing/regulatory trends, global licensing and investment trends, and new partnership models. Syneos Health also provides Virtual Incubating for biotech companies under KIMCo's cultivation programs.
• GCCL (지씨씨엘)minorStrategic or Co-development Partner · 1 January 2026KIMCo and GCCL signed an MOU for clinical research support for biotech ventures. The partnership provides biomarker co-discovery, customized assay development, and clinical design consulting for early-stage biotech ventures invested in by KIMCo, aiming to produce globally competitive outcomes.
• Chungbuk Creative Economy & Innovation Center (충북창조경제혁신센터)coreStrategic or Co-development Partner · 1 January 2026KIMCo and Chungbuk Creative Economy & Innovation Center were jointly selected as the dedicated institution for the Ministry of SMEs' 'Technology Commercialization Package Support Project' in the pharma-biotech sector. The program provides biotech companies with technology and business diagnosis, commercialization strategy development, professional consulting, and investment and pharmaceutical company partnership linkage.
• Nordic Life Science Days / Business SwedenmajorStrategic or Co-development Partner · 1 October 2025KIMCo co-hosted 'K-Bio Innovation Seminar: Cross-border Collaboration & ATMP Frontiers' at Nordic Life Science Days in Gothenburg, Sweden with Chungbuk & Incheon Creative Economy Innovation Centers and Business Sweden. The seminar featured presentations on the K-bio ecosystem and investment market, and included IR pitching by 10 Korean cell and gene therapy ventures. KIMCo also held discussions on cross-border investment and joint fund creation with Nordic venture capital.
• Bae, Kim & Lee LLC (법무법인 태평양)coreImplementation/ SI/ Consulting Partner · 23 July 2025KIMCo signed an MOU with Bae, Kim & Lee LLC for mutual cooperation to promote innovative growth of the pharma-biotech industry ecosystem. The partnership provides investment cultivation support for domestic biotech companies, innovation growth support, industry insight sharing, and networking activities. BKL provides specialized support for biotech startup scale-up and global expansion, including investment contracts, IP strategy, and technology transfer agreements.
• SNU Center for Entrepreneurship & Innovation (서울대학교 창업지원단)majorStrategic or Co-development Partner · 10 June 2025KIMCo signed an MOU with Seoul National University's Center for Entrepreneurship & Innovation to cooperate in discovering and fostering promising startups and activating investment in the pharma-biotech and healthcare sectors. The partnership connects SNU's promising technologies with KIMCo's industry expertise and network to support value-up of early-stage startups.
• Yonsei University Bio-Health Technology Holdings (연세대 바이오헬스기술지주)majorStrategic or Co-development Partner · 18 March 2025KIMCo signed an MOU with Yonsei University Bio-Health Technology Holdings (Korea's first bio-health specialized technology holding company) to cooperate in discovering and fostering promising pharma-biotech and healthcare startups and activating investment. The partnership combines medical and industrial expertise and networks to support early-stage company value-up and strengthen global competitiveness of Korea's pharma-biotech industry.
• Japanese Big Pharma (Takeda, Astellas, Mitsubishi Tanabe)coreStrategic or Co-development Partner · 26 February 2025Following KIMCo's participation in the 2nd and 3rd Korea-Japan Bio Ecosystem Round Tables in Tokyo (organized by Ministry of SMEs), KIMCo established cooperation networks with Japanese Big Pharma companies including Takeda, Astellas, and Mitsubishi Tanabe. KIMCo plans to pursue in-licensing, research collaboration, and various partnership opportunities between KIMCo member companies and these Japanese Big Pharma companies.
• Korean Science and Technology Holdings (한국과학기술지주, KST)coreStrategic or Co-development Partner · 1 January 2025KIMCo and KST signed an MOU for bio-health technology commercialization and startup ecosystem activation. They agreed to jointly discover and evaluate promising bio-health technologies and startups, cooperate in planning-type technology commercialization and company builder collaboration, operate portfolio company cultivation programs, and link open innovation with global commercialization.
• Boehringer Ingelheim (베링거잉겔하임) & Boehringer Ingelheim Venture Fund (BIVF)coreStrategic or Co-development Partner · 1 January 2024KIMCo and Boehringer Ingelheim & BIVF co-hosted a Biotech Venture Meet-up Day for Korean promising biotech companies developing anti-cancer drug candidates. Six companies that passed BI and BIVF document review were invited for one-on-one meetings. KIMCo continues to monitor and support partnership outcomes between the companies and BI & BIVF.
• K-Bio Lab Hub Business Promotion Team (K-바이오랩허브사업추진단)majorStrategic or Co-development Partner · 1 January 2024KIMCo signed an MOU with the K-Bio Lab Hub Business Promotion Team under the Korea Technology and Information Promotion Institute for SMEs to discover and foster innovative pharma-biotech startups. Cooperation areas include joint program planning for global open innovation, joint development and expansion of startup support programs, linkage for startup investment financing, and sharing of expert consulting groups.
• JLABS Korea / Johnson & Johnson (J&J)coreStrategic or Co-development Partner · 1 January 2023KIMCo and JLABS Korea have an ongoing partnership to activate open innovation in Korea's pharma-biotech industry. J&J is actively exploring Korean pharma-biotech assets for in-licensing, research collaboration, and investment opportunities. JLABS Korea provides pre-screening support for KIMCo member company assets matching J&J's focus therapeutic areas and connects them with J&J partnerships. They co-host 'KIMCo-JLABS Korea Synergy Night' and 'Partnerhip Day' events with Johnson & Johnson Innovative Medicine.
• Hongneung Bio-cluster (홍릉강소특구사업단)majorStrategic or Co-development Partner · 29 September 2021KIMCo and Seoul Hongneung Bio-cluster signed an MOU to commercialize innovative pharma-biotech technologies. They cooperate on technology commercialization activation, R&D partnering and network building, industry-academia-government-hospital-finance ecosystem creation, and demand-driven innovation technology discovery and technology commercialization cooperation program operation.
• Vaccine Practical Application Technology Development Business Group (백신실용화기술개발사업단)majorStrategic or Co-development Partner · 27 September 2021KIMCo and the Vaccine Practical Application Technology Development Business Group signed an MOU to build a public-private cooperation ecosystem for vaccine development. They cooperate on joint discovery and execution of vaccine-related research projects and supporting commercialization activities, and on production infrastructure, new drug development, and global market commercialization support for domestic vaccine and biotech companies.
• Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA, 한국제약바이오협회)coreStrategic or Co-development PartnerKPBMA co-founded KIMCo as the primary organizational partner, providing institutional support and industry leadership. KIMCo was established with KPBMA and 59 member companies contributing to the foundation's capital.
• Ministry of SMEs and Startups (중소벤처기업부)coreOthersKIMCo operates as the designated operating institution for the Ministry of SMEs and Startups' programs including Smart Factory construction support, technology commercialization package support, and Global Cooperation Type R&D. The Ministry provides the government funding that KIMCo distributes to member companies.
• Ministry of Food and Drug Safety (식품의약품안전처)coreOthersKIMCo operates as the contracted institution for MFDS's QbD system roll-out support project, providing QbD consulting and expert training programs to pharmaceutical companies.
• Ministry of Trade, Industry and Energy (산업통상자원부)coreOthersKIMCo is the designated operating institution for MOTIE's TBM development project and mRNA vaccine raw material production advancement technology development project, providing support to pharmaceutical companies for global market entry and vaccine technology development.
• Deloitte APACminorStrategic or Co-development PartnerDeloitte APAC's Yongho Lee (이용호 이사) served as speaker at KIMCo's '2026 Life Sciences and Healthcare Industry Outlook' webinar, providing strategic insights on global pharma-biotech industry trends and growth opportunities.
• KOTRA (한국무역투자진흥공사)minorChannel Partner/ Reseller/ DistributorKOTRA is a partner in the Korea-Europe Biomedical Partnership Project, supporting Korean pharmaceutical companies in forming demand-based collaborative relationships with global pharmaceutical companies, innovative biotech companies, and bio-clusters in Europe.
• Korea Health Industry Development Institute (한국보건산업진흥원, KHIDI)minorStrategic or Co-development PartnerKHIDI and KIMCo co-authored a public-private partnership case study report in the pharmaceutical industry, providing research on partnership models and collaborative strategies for industry growth.
• 54 Korean Pharmaceutical Companies (Member Companies)coreStrategic or Co-development Partner59 pharmaceutical and biotech companies are contributing founding members of KIMCo, including major companies such as Daewoong, GC绿十字, JW Pharmaceutical, Yuhan, Hanmi, HK inno.N, LG Chem Life Sciences, SK bioscience, Boryung, Chong Kun Dang, Dong-A ST, Il Dong Pharmaceutical, and others. These companies participate in KIMCo's board of directors and operating committee.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• WuXi AppTec: China-headquartered global CRO/CDMO and life-sciences services platform with extensive open-innovation and venture-incubation activities. A much larger, for-profit incumbent that competes for biotech venture attention and provides similar R&D enablement, though commercial rather than non-profit.

Direct peers

• Yozma Group (Israel): Historic Israeli government-backed venture initiative that seeded Israel's life-sciences VC industry through a public-private model. Conceptually analogous to KIMCo as a government-anchored capital catalyst for the domestic life-sciences industry.
• KoreaBIO (Korean Bio Association): National trade association representing Korea's biotech industry, distinct from KPBMA which represents pharmaceutical manufacturers. Closely comparable as a Korean industry association promoting biotech sector growth and connecting industry players.
• Life Science Innovation Network Japan (LINK-J): Japan's premier life-sciences open-innovation platform founded in 2016, connecting academia, startups, and global pharma. Highly comparable to KIMCo as an industry-coordinated non-profit hub bridging venture-pharma-global partners in the Japanese pharma ecosystem.
• BioIndustry Association (BIA): UK trade association for the life-sciences industry representing member companies and connecting them with investors, policymakers, and global partners. Comparable in mission (advocating for and connecting the UK life-sciences industry) and member-driven structure to KIMCo.
• Korea Health Industry Development Institute (KHIDI): Government-affiliated Korean institute supporting health-industry development including pharma and biotech R&D, global market entry, and public-private partnerships. Directly comparable as a public-private partnership operator in Korean pharma, and a documented KIMCo co-author.
• Massachusetts Life Sciences Center (MLSC): US state-level quasi-governmental agency that funds and accelerates life-sciences innovation in Massachusetts through grants, investments, and industry partnerships. Comparable as a publicly-aligned pharma-biotech ecosystem orchestrator with capital deployment and program administration functions similar to KIMCo.

Others

• BioCentury-BayHelix: Industry organizer of the East-West Biopharma Summit and other cross-border life-sciences partnering events that KIMCo co-organizes. Comparable as a cross-border pharma-biotech connection facilitator between US/West and Asia.

Emerging players

• JLABS (Johnson & Johnson): J&J's global network of life-sciences incubators providing lab space, mentorship, and funding to early-stage biotech startups. KIMCo already partners with JLABS Korea; comparable as an open-innovation intermediary between Big Pharma and biotech ventures, though JLABS is a corporate program rather than an industry consortium.

Regional players

• California Life Sciences Association (CLS): US state-level life-sciences advocacy and ecosystem organization for California. Comparable in industry-association role and ecosystem-building function, but focused on the US market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kimco-korea-innovative-medicines-consortium

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KIMCO